136 related articles for article (PubMed ID: 10227461)
21. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
22. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
23. Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease.
Pulsoni A; Villivà N; Cavalieri E; Falcucci P; La Verde G; Matera R; Petrucci MT; Tosti ME; Mandelli F
Drugs Aging; 2002; 19(12):947-53. PubMed ID: 12495369
[TBL] [Abstract][Full Text] [Related]
24. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
26. Clinical staging and therapeutic results in multiple myeloma.
Santoro A; Schieppati G; Franchi F; Valagussa P; Monfardini S
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1353-9. PubMed ID: 6685627
[TBL] [Abstract][Full Text] [Related]
27. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
[TBL] [Abstract][Full Text] [Related]
28. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.
Gulbrandsen N; Wisløff F; Nord E; Lenhoff S; Hjorth M; Westin J;
Eur J Haematol; 2001 May; 66(5):328-36. PubMed ID: 11422413
[TBL] [Abstract][Full Text] [Related]
29. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma.
Kouroukis CT; O'Brien BJ; Benger A; Marcellus D; Foley R; Garner J; Ingram C; Haines P; Henderson-O'Connor N; Meyer R
Leuk Lymphoma; 2003 Jan; 44(1):29-37. PubMed ID: 12691140
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
32. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
Le Blanc R; Montminy-Métivier S; Bélanger R; Busque L; Fish D; Roy DC; Kassis J; Boileau J; Lavallée R; Bélanger D; Letendre F; Hébert J; Sauvageau G; Perreault C; Roy J
Bone Marrow Transplant; 2001 Nov; 28(9):841-8. PubMed ID: 11781644
[TBL] [Abstract][Full Text] [Related]
35. Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG).
Keldsen N; Bjerrum OW; Dahl IM; Drivsholm A; Ellegaard J; Gadeberg O; Gimsing P; Grønvold T; Hansen MM; Hippe E
Eur J Haematol; 1993 Aug; 51(2):80-5. PubMed ID: 8370422
[TBL] [Abstract][Full Text] [Related]
36. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
37. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H;
Lancet; 2007 Oct; 370(9594):1209-18. PubMed ID: 17920916
[TBL] [Abstract][Full Text] [Related]
38. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden.
Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
Eur J Haematol; 1993 Feb; 50(2):95-102. PubMed ID: 8440364
[TBL] [Abstract][Full Text] [Related]
39. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.
Kristinsson SY; Landgren O; Dickman PW; Derolf AR; Björkholm M
J Clin Oncol; 2007 May; 25(15):1993-9. PubMed ID: 17420512
[TBL] [Abstract][Full Text] [Related]
40. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
Westin J
Semin Oncol; 1991 Oct; 18(5 Suppl 7):37-40. PubMed ID: 1948128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
